Antitrust: Aspen proposes 73% price reduction for six off-patent cancer medicines to remove Commission’s excessive pricing concerns


(Credit: Unsplash)

This article is brought to you in association with the European Commission.

The European Commission invites comments from all interested parties on commitments submitted by Aspen to address the Commission’s concerns over excessive pricing as regards six off-patent cancer medicines. Aspen proposes to reduce its prices in Europe for these medicines by 73% on average. In addition, Aspen proposes to ensure the continued supply of the medicines for a significant period. Comments can be sent within two months from the publication of the commitments in the Official Journal. The Commission will then take a final view as to whether the commitments sufficiently address competition concerns.

For more details, including on the next steps in the investigation, please see the press release.

  1. Which medicines and countries do the proposed commitments cover?

The commitments proposed by Aspen cover all medicines and all Member States for which the Commission identified competition concerns.


The commitments cover six off-patent prescription medicines that are used in the treatment of certain types of cancer and mainly haematological cancers, such as multiple myeloma, chronic lymphocytic leukaemia or acute lymphocytic leukaemia. Some of these medicines are used only by small patient groups. The medicines are mostly sold under the brand names Alkeran 2 mg Tablets, Alkeran IV / 50mg (Intravenous), Purinethol, Leukeran, Lanvis and Myleran and contain the active ingredients melphalan, mercapto­purine, chlorambucil, tioguanine and busulfan. Aspen acquired these six cancer medicines from another company in 2009. Their patent protection had expired 50 years ago.


Aspen’s proposed commitments cover the entire European Economic Area (EEA), except Italy, where a decision by the Italian competition authority was taken in 2016 (upheld in the last instance in March 2020) regarding the Italian market and the same medicines (except Myleran). The six medicines are each sold in a different number of countries, so the commitments concern for each of the medicines a different list of countries.

  1. What do the proposed commitments aim at achieving?

The proposed commitments aim at bringing to an end Aspen’s suspected excessive pricing conduct with respect to its six off-patent cancer medicines, which the Commission suspects to constitute an abuse of a dominant position. The commitments would achieve this by introducing quick, tangible and lasting changes in the markets for each of the six products and in each country where the medicines are sold. They would (i) immediately apply price reductions to Aspen’s net prices, (ii) impose a ten-year price-ceiling, and (iii) guarantee supply:

(i) Reduction in prices

The net prices to wholesalers for each of the six cancer medicines would significantly drop in all markets where Aspen’s current prices raise concerns under the EU competition rules. On average, Aspen’s net prices would drop by approximately 73% across all the medicines and Member States concerned.

For most of the medicines and on average, the reduced net prices would be below the levels of 2012, when Aspen started its strategy of high price increases. After the price reductions, the net wholesale prices for the various medicines would still differ between Member States. This is because the reduced prices have been determined on the basis of Aspen’s costs which differ considerably across products and Member States. The reduced net wholesale prices for each product and for each Member State are set out in Table 1 of the proposed commitments.

(ii) Ten-year price ceiling

The prices proposed in the commitments are maximum net prices (price ceilings). This means that prices are not fixed and Aspen is free to charge and agree with Member States on lower prices.

The price ceilings would apply for a period of ten years from the day following the Commission’s decision declaring the commitments binding. During the second half of that ten-year period, Aspen would be entitled to one possible review of the net price ceilings by the Commission, with the support of an independent monitoring trustee, but only if Aspen’s costs linked to the medicines increase significantly (by at least 20%). Any resulting change in the net price ceilings would be proportionate to any cost increase, and, as part of the review process, the Commission would, ensure that the revised ceiling does not raise any concerns over excessive prices.

(iii) Continued supply of medicines

Aspen would commit, first, to the continued supply of the six cancer medicines for a guaranteed minimum period of five years (2020-2024).

Then, for a second five-year period (2025-2029), Aspen would commit to either continue supplying the medicines, or, if it decides to stop the sale of a given product in a given country, to help continued supply by (i) giving a one-year’s notice to the national authorities concerned; (ii) at the same time making the medicines’ marketing authorisations available for sale to any third party that is interested in taking over supply; and (iii) maintaining the registration of the marketing authorisations until their transfer to another supplier.

  1. How would it be ensured that the price reductions are implemented in compliance with rules on pricing and reimbursement of each Member State?

Price reductions for medicines may be subject to national pricing and reimbursement procedures, e.g. where so-called formal ‘list prices’ need to change. Where this is the case, Aspen would be required to submit immediately applications for list price reductions, in compliance with applicable national procedures. Aspen would also have a duty to proactively assist the relevant regulatory authorities to achieve the price reductions.

  1. From when and for how long would the reduced prices apply?

The reduced net wholesale prices would apply if and as soon as the Commission accepts them and would remain capped at that level for the following ten years. In addition, the reduced prices would be applied retroactively as of 1 October 2019, date on which Aspen concretely proposed commitments to the Commission. To apply the price reductions already from that date, Aspen would grant a rebate for any amount charged that exceeds the reduced net prices. Aspen would pay that rebate to the public and private entities in the Member States that ultimately paid or reimbursed Aspen’s medicine prices. In the two Member States where limited co-payment existed, also patients would receive a small rebate. The rebates would apply for the period until the medicines’ list prices change or, where list prices do not form part of the national system, until Aspen’s reduced net wholesale prices become otherwise effective. The rebates would therefore also ensure that no health system or patient pays excessive prices during this transitional period.

  1. Why is it important to ensure the supply of the six cancer medicines?

The commitments proposed by Aspen concern the price of six off-patent medicines that are critical for the treatment of patients suffering from certain types of life-threatening cancer, such as leukaemia and multiple myeloma. For patients, it is not only important that the medicines are not sold at excessive prices, but also that the medicines continue to be available in their country. For this reason, the commitments not only envisage a ten-year price ceiling, but also contribute to ensuring supply for ten years.

  1. How would the implementation of the proposed commitments be monitored?

After taking into account all the comments received in response to its market test notice and the proposed commitments, the Commission will take a final view as to whether the proposed commitments address its competition concerns, eventually adopting a decision making the commitments legally binding on Aspen.

Aspen’s compliance with the commitments will be monitored for their entire duration by an independent monitoring trustee, approved by the Commission. The trustee has reporting obligations to the Commission, for example, on Aspen’s progress and timing in implementing the maximum reduced net prices in various Member States. In the event that Aspen does not comply with the commitments, the trustee may also propose measures to Aspen within a specified timeframe to ensure compliance.

  1. How was Aspen able to impose very high prices for the medicines?

Based on the Commission’s preliminary assessment, for most of the six medicines there were no alternative suppliers and, in the few Member States where other pharmaceutical companies entered the market, they did so only recently. Furthermore, the medicines are essential medicines; patients depend on them. National pricing and reimbursement authorities were under pressure to ensure the supply of these medicines to patients and effectively had little option but to agree to Aspen’s price increase requests. Aspen even went as far as threatening to withdraw the medicines from the national list of reimbursable medicines and in some cases was ready to withdraw from normal supply in the Member State.

  1. To what extent has the Commission worked together with Member States on this and other suspected excessive pricing cases in the sector?

Through the European Competition Network, the Commission works regularly and closely together with national competition authorities, including in the pharmaceutical sector. Regarding Aspen’s pricing practices, the Commission has cooperated very closely with the Italian competition authority, both in the proceedings against Aspen in Italy (see under Question 1) and those at EU level. National competition authorities may indeed take action against suspected violations of EU competition law on national markets where they have early on sufficient evidence at their disposal. Where it then turns out that the same conduct exists (and persists) also in other Member States or across the EU, the Commission may decide to launch an investigation as well.

In the Aspen case, the Commission was also in close contact with national health authorities to, amongst others, seek information on Aspen’s conduct in the various Member States, and on how the proposed commitments, if accepted, could be implemented at national level. More generally, national regulators and national health authorities play an important role in designing and implementing effective regulatory frameworks regarding medicine prices and reimbursement. In very specific circumstances, EU competition rules may also apply, namely when a firm in a dominant position imposes such high prices that they amount to excessive prices within the meaning of the EU competition rules. Continuous efforts by all private and public stakeholders are needed to meet the societal challenge of ensuring access to affordable and innovative medicines.

the sting Milestones

Featured Stings

Can we feed everyone without unleashing disaster? Read on

These campaigners want to give a quarter of the UK back to nature

How to build a more resilient and inclusive global system

Stopping antimicrobial resistance would cost just USD 2 per person a year

Focus on EU’s external action and building our stronger inner core: von der Leyen at the Special European Council

EU to finance new investment projects with extra borrowing; French and Italian deficits to be tolerated

How responsible businesses can step forward to fight coronavirus

‘Crippling to our credibility’ that number of women peacekeepers is so low: UN chief

Italy’s populist government appears determined to drive EU economy and markets into recession

Women outliving men ‘everywhere’, new UN health agency statistics report shows

4 ways governments can support start-ups and save their economies

UN chief condemns deadly attacks in Afghanistan

The Indian miracle state pointing the way to global sustainability

How studying genetics and lifestyle can shape a healthier MENA region

Trade: EU-Singapore agreement to enter into force on 21 November 2019

‘Grave consequences’ await if new deadly escalation of violence in Gaza continues – top UN official

EU Parliament approves CETA: the EU-Canada free trade deal sees the light in Trump’s gloomy era

Writing a new story in gender inequalities: women gaining space and respect in medicine

Asia and Pacific on course to miss all Sustainable Development Goals, says UN region chief

Unanswered questions for Europe’s youth in President Juncker’s State of Union

INTERVIEW: UN’s top official in North Korea foresees ‘surge’ in humanitarian aid

Despite progress, companies face gender equality ‘backlash’: UN business body

International partners pledge $1.2 billion to help cyclone-hit Mozambique recover, ‘build back better’

ITU Telecom World 2016: it’s all about working together

We’re facing a ‘cold crunch,’ and it’s nothing to do with the polar vortex

How we can build our way out of the crisis

Suffering of thousands of war-affected Syrian children ‘unprecedented and unacceptable’

FROM THE FIELD: India’s plastic waste revolution

Post-Brexit muddled times: the resignation of UK’s top ambassador and Theresa May’s vague plans

Can the EU afford to block China’s business openings to Europe by denying her the ‘market economy status’?

Worldwide UN family celebrates enduring universal values of human rights

How bad is the Eurozone economy? The ECB thinks too bad

6.1 billion EUR for sustainable fisheries and safeguarding fishing communities

Libya: Attack on foreign ministry, an attack on all Libyans, stresses UN envoy

Coldplay stop touring to save the world: is pop music going sustainable?

These are the world’s most tree-covered countries

Pakistan: UN strongly condemns terrorist attack that leaves scores dead and wounded at election rally

COP21 Breaking News_03 December: Unprecedented Global Alliance for Buildings and Construction to Combat Climate Change

First calls under Horizon Europe to be launched by the European Research Council

Women ‘vital’ to peace efforts and ensuring long-lasting stability in Afghanistan

Amazon wildfires are tomorrow’s breathtaker

UN chief condemns explosion at election rally in Zimbabwe that injured dozens, including senior politicians

This incredibly detailed map of Africa could help aid and development

EU Citizenship Report: empowering citizens and protecting their rights

Use “blockchain” model to cut small firms’ costs and empower citizens, urge MEPs

“ASEM: Global Partners for Global Challenges”, a Sting Exclusive by China’s Ambassador to the EU

115 rejections and no pay. What it really takes to be an entrepreneur

What Mary Poppins teaches us about behavioural economics

The economic cost of anti-vaccination movements in Italy

Medical students and their ability to edify women’s rights

Reconciliation helps ‘repair fractures’, enable lasting peace, Security Council hears

The challenge to be a good healthcare professional

Drought in Europe: Member States agree on support measures proposed by the Commission

State aid: Commission approves €24.7 million of Italian support to compensate Alitalia for further damages suffered due to coronavirus outbreak

This is the world’s greenest football club – and you’ve probably never even heard of it

EU budget: Commission proposes major funding increase for stronger borders and migration

11 lessons the history of business can teach us about its future

The road ahead to building a more sustainable world

Protests, violence in Haiti prompts international call for ‘realistic and lasting solutions’ to crisis

Mental health and suicide prevention: the contradictory access in a reference city of southern Brazil

Coronavirus: a common path to Europe’s safe re-opening

UN launches innovative programme to detect and disrupt terrorist travel

Superbugs: MEPs advocate further measures to curb use of antibiotics

The World Bank’s 2020 country classifications explained

More Stings?

Speak your Mind Here

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s